Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer
Tristan Gallenne (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis, Merus BV)
Kenneth N. Ross (Massachusetts General Hospital, Harvard Medical School)
Nils L. Visser (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
undefined Salony (Massachusetts General Hospital, Harvard Medical School)
Christian J. Desmet (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Ben S. Wittner (Harvard Medical School, Massachusetts General Hospital)
Lodewyk Wessels (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis, TU Delft - Pattern Recognition and Bioinformatics)
Sridhar Ramaswamy (Massachusetts General Hospital, Harvard-Ludwig Center for Cancer Research, Harvard Medical School, Broad Institute of MIT and Harvard)
Daniel Ss Peeper (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Prognostic classifiers conceivably comprise biomarker genes that functionally contribute to the oncogenic and metastatic properties of cancer, but this has not been investigated systematically. The transcription factor Fra-1 not only has an essential role in breast cancer, but also drives the expression of a highly prognostic gene set. Here, we systematically perturbed the function of 31 individual Fra-1-dependent poor-prognosis genes and examined their impact on breast cancer growth in vivo. We find that stable shRNA depletion of each of nine individual signature genes strongly inhibits breast cancer growth and aggressiveness. Several factors within this ninegene set regulate each other's expression, suggesting that together they form a network. The nine-gene set is regulated by estrogen, ERBB2 and EGF signaling, all established breast cancer factors. We also uncover three transcription factors, MYC, E2F1 and TP53, which act alongside Fra-1 at the core of this network. ChIP-Seq analysis reveals that a substantial number of genes are bound, and regulated, by all four transcription factors. The nine-gene set retains significant prognostic power and includes several potential therapeutic targets, including the bifunctional enzyme PAICS, which catalyzes purine biosynthesis. Depletion of PAICS largely cancelled breast cancer expansion, exemplifying a prognostic gene with breast cancer activity. Our data uncover a core genetic and prognostic network driving human breast cancer. We propose that pharmacological inhibition of components within this network, such as PAICS, may be used in conjunction with the Fra-1 prognostic classifier towards personalized management of poor prognosis breast cancer.
help_outline